Literature DB >> 15010070

Long-term survivors of ovarian malignancies after cisplatin-based chemotherapy; cardiovascular risk factors and signs of vascular damage.

F Y F L de Vos1, J Nuver, P H B Willemse, A G J van der Zee, J Messerschmidt, J G M Burgerhof, E G E de Vries, J A Gietema.   

Abstract

Male germ cell tumour patients treated with cisplatin-based chemotherapy frequently develop cardiovascular risk factors and disease, but sparse information is available about long-term complications of this type of chemotherapy in women. We investigated the prevalence of cardiovascular risk factors and vascular damage in 21 women (median age 39 years; range 26-57 years) with an epithelial or germ cell tumour of the ovary cured by cisplatin-based chemotherapy after a median follow-up of 14 years (range 3-21 years). Hypercholesterolaemia was present in 62%, obesity in 24%, hypertension in 14%, insulin resistance in 14%, and microalbuminuria in 24% of patients. Microalbuminuria was more frequent in long-term cancer survivors than in a female background population with a similar age (23.8 versus 3.2%; P<0.05). A substantial portion of young female patients cured by cisplatin-based chemotherapy are likely to develop cardiovascular risk factors and signs of endothelial damage at an early stage.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15010070     DOI: 10.1016/j.ejca.2003.11.026

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  9 in total

Review 1.  Management of VEGF-Targeted Therapy-Induced Hypertension.

Authors:  Stefano Caletti; Anna Paini; Maria Antonietta Coschignano; Carolina De Ciuceis; Matteo Nardin; Roberto Zulli; Maria Lorenza Muiesan; Massimo Salvetti; Damiano Rizzoni
Journal:  Curr Hypertens Rep       Date:  2018-06-29       Impact factor: 5.369

2.  Pilot study of vascular health in survivors of osteosarcoma.

Authors:  Daniel A Mulrooney; Kirsten K Ness; Sujuan Huang; Anna Solovey; Robert P Hebbel; James D Neaton; Denis R Clohisy; Aaron S Kelly; Joseph P Neglia
Journal:  Pediatr Blood Cancer       Date:  2013-05-30       Impact factor: 3.167

3.  Homing and restorative effects of bone marrow-derived mesenchymal stem cells on cisplatin injured ovaries in rats.

Authors:  Jiabin Liu; Haiying Zhang; Yun Zhang; Nan Li; Yuku Wen; Fanglei Cao; Hao Ai; Xiaoou Xue
Journal:  Mol Cells       Date:  2014-11-10       Impact factor: 5.034

Review 4.  Vascular Complications of Cancer Chemotherapy.

Authors:  Alan C Cameron; Rhian M Touyz; Ninian N Lang
Journal:  Can J Cardiol       Date:  2015-12-28       Impact factor: 5.223

5.  Recovery of ovarian function by human embryonic stem cell-derived mesenchymal stem cells in cisplatin-induced premature ovarian failure in mice.

Authors:  Sook Young Yoon; Jung Ah Yoon; Mira Park; Eun-Young Shin; Sookyung Jung; Jeoung Eun Lee; Jin Hee Eum; Haengseok Song; Dong Ryul Lee; Woo Sik Lee; Sang Woo Lyu
Journal:  Stem Cell Res Ther       Date:  2020-06-26       Impact factor: 6.832

6.  The impact of cisplatinum-based chemotherapy on ventricular function and cardiovascular risk factors in female survivors after malignant germ cell cancer.

Authors:  Klaus Murbraech; Olesya Solheim; Hanne M Aulie; Sophie D Fossa; Svend Aakhus
Journal:  ESC Heart Fail       Date:  2015-07-14

Review 7.  Molecular characteristics of malignant ovarian germ cell tumors and comparison with testicular counterparts: implications for pathogenesis.

Authors:  Sigrid Marie Kraggerud; Christina E Hoei-Hansen; Sharmini Alagaratnam; Rolf I Skotheim; Vera M Abeler; Ewa Rajpert-De Meyts; Ragnhild A Lothe
Journal:  Endocr Rev       Date:  2013-04-10       Impact factor: 19.871

8.  Endometrial mesenchymal stem cells isolated from menstrual blood repaired epirubicin-induced damage to human ovarian granulosa cells by inhibiting the expression of Gadd45b in cell cycle pathway.

Authors:  Zhongrui Yan; Fengyi Guo; Qing Yuan; Yu Shao; Yedan Zhang; Huiyan Wang; Shaohua Hao; Xue Du
Journal:  Stem Cell Res Ther       Date:  2019-01-03       Impact factor: 6.832

Review 9.  Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients.

Authors:  Daan C H van Dorst; Stephen J H Dobbin; Karla B Neves; Joerg Herrmann; Sandra M Herrmann; Jorie Versmissen; Ron H J Mathijssen; A H Jan Danser; Ninian N Lang
Journal:  Circ Res       Date:  2021-04-01       Impact factor: 17.367

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.